Welcome to our congress
“Vision 2030: Changing Paradigms in IBD”
on 19 – 20 May 2023
About the TRR 241
The TRR 241 is a joint research network of researchers in Erlangen, Berlin, Kiel and Innsbruck supported by the German Research Foundation (DFG). The goal of the TRR 241 is to better understand the molecular and cellular processes that lead to the development of Inflammatory Bowel Diseases (IBD).
Our research network brings together a group of highly experienced gastroenterologists, immunologists and cellular and molecular biologists with expertise in experimental, translational and clinically-oriented research to ensure the realization of our goals. The driving hypothesis of our consortium is that a dysregulated signal exchange between the microbiota, the gut epithelium and immune cells is a key driver in the pathogenesis of IBD.
The research program has been designed to advance not only basic concepts of IBD development, but also to provide an outstanding platform for translational studies and pre-clinical and clinical testing.
MORE INFORMATION ABOUT THE TRR 241:
Agenda
FRIDAY, 19th May 2023
| 12.00 | Get together / Business lunch |
| 1.00 | Welcome and Introduction Britta Siegmund & Christoph Becker |
SESSION I – INTESTINAL INFLAMMATION – KEY PATHWAYS
CHAIR: Carl Weidinger / Susanne Krug
| 1.30 | Matthias Friedrich, Oxford, UK ‘Histo-molecular Stratification of Inflammatory Bowel Diseases for Medical Therapy’ |
| 2.00 | Gerhard Krönke, Berlin, Germany ‘Molecular checkpoints regulating onset and resolution of the inflammatory response’ |
| 2.30 | Maria Rescigno, Milan, IT ‘Gut-brain vascular interactions in colitis’ |
| 3.00 | Sebastian Zundler, Erlangen, DE ‘Immune cell trafficking circuits in intestinal inflammation and beyond’ |
| 3.30 | Coffee break |
SHORT TALKS – SELECTED FROM ABSTRACTS
CHAIR: Kristina Koop / Antigoni Triantafyllopoulou
| 4.00 | Martina Macino, Berlin, DE ‘Uncovering the role of somatic mosaicism in the intestinal crypts of IBD patients’ |
| 4.15 | Julia Hecker, Berlin, DE Hendrik Grapp, Erlangen, DE ‘Role of IL-36 signaling in IBD’ |
| 4.35 | Rashmita Pradhan, Erlangen, DE Lili Bao, Erlangen, DE ‘Mitochondrial dysfunction in IBD‘ |
SESSION II – LUMINAL FACTORS INFLUENCING INTESTINAL
INFLAMMATION AND BEYOND
CHAIR: Kai Hildner / Britta Siegmund
| 5.00 | Timon Adolph, Innsbruck, AT ‘Dietary lipids fueling IBD’ |
| 5.30 | Noah Palm, New Haven, US ‘Mapping uncharted landscapes of host-microbiota connectivity’ |
| 6.00 | Harry Sokol, Paris, FR ‘Alteration of Host and Microbiome tryptophan metabolism in IBD’ |
| 6.30 | Petra Bacher, Kiel, DE ‘Pathogenic CD4+ T cell responses against intestinal fungi in IBD’ |
| 7.00 | Closing remarks |
| 7.30 | Speakers Dinner |
SATURDAY, 20th May 2023
SESSION III – MEMORY AND ANITGEN-SPECIFIC RESPONSE
CHAIR: Christoph Becker / Nathalie Britzen-Laurent
| 8:30 | Mathieu Uzzan, France/US ‘The intestinal B-cell response in inflammatory bowel disease’ |
| 9.00 | Thomas Vogl, Wien, AT ‘Deciphering human antibody repertoires against the microbiome in health and disease’ |
| 9.30 | Andrew Macpherson, Bern, CH ‘Determination of microbiota-specific adaptive immune responses‘ |
| 10.00 | Caroline Bosch-Voskens, Erlangen, DE ‘Treatment of refractory ulcerative colitis with autologous adoptively transferred ex-vivo expanded regulatory T cells’ |
| 10.30 | Coffee break |
| 11.00 | POSTER SESSION |
| 1.00 | Lunch |
SESSION IV – INTESTINAL INFLAMMATION: UNEXPECTED
NETWORKS
CHAIR: Jay Patankar / Andreas Diefenbach
| 2.00 | Jody Rosenblatt, London, UK ‘Asthma: putting the squeeze on airway epithelia – implications for IBD’ |
| 2.30 | Matthieu Allez, Paris, FR ‘The postoperative model in Crohn’s disease’ |
| 3.00 | David Artis, New York, US ‘Regulation of intestinal immunity’ |
| 3.30 | Manuel Jakob, Berlin, DE ‘ILC3s restrict the dissemination of intestinal bacteria to safeguard liver regeneration after surgery’ |
| 4.00 | Coffee break |
SESSION V – TACKLING IBD WITH SYSTEMS BIOLOGY
CHAIR: Ashley Sanders / Clemens Neufert
| 4.30 | Aline Azabdaftari, Oxford, UK ‘Epithelial defects in monogenic inflammatory bowel disease’ |
| 5.00 | Ahmed Hegazy, Berlin, DE ‘Interleukin 22 – oncostatin M axis promotes inflammation and tumorigenesis in the intestine’ |
| 5.30 | Eduardo J. Villablanca, Stockholm, SE ‘Systems approach to identify novel mechanisms promoting mucosal healing in IBD’ |
| 6.00 | Zlatko Trajanoski, Innsbruck, AT ‘IBDome’ |
| 6.30 | Closing remarks |